GLP-1 agonists: superior for mind and body in
antipsychotic-treated patients?

J 2022

GLP-1 agonists: superior for mind and body in antipsychotic-treated patients?

HORSKÁ, Kateřina, Jana RUDÁ and Silje SKREDE

Basic information

Original name

GLP-1 agonists: superior for mind and body in antipsychotic-treated patients?

Name in Czech

GLP-1 agonisté: superiorní pro mozek a tělo u pacientů léčených antipsychotiky?

Authors

HORSKÁ, Kateřina (203 Czech Republic, belonging to the institution), Jana RUDÁ (203 Czech Republic, guarantor, belonging to the institution) and Silje SKREDE (578 Norway)

Edition

TRENDS IN ENDOCRINOLOGY AND METABOLISM, LONDON, ELSEVIER SCIENCE LONDON, 2022, 1043-2760

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30104 Pharmacology and pharmacy

Country of publisher

United States of America

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

URL

Impact factor

Impact factor: 10.900

RIV identification code

RIV/00216224:14110/22:00126321

Organization unit

Faculty of Medicine

DOI

http://dx.doi.org/10.1016/j.tem.2022.06.005

UT WoS

000877913500003

Keywords in English

antipsychotic; metabolic adverse effects; GLP-1 receptor agonist; pro-cognitive; schizophrenia

Abstract

V originále

Antipsychotics (APDs) represent a core treatment for severe mental disorders (SMEs). Providing symptomatic relief, APDs do not exert therapeutic effects on another clinically significant domain of serious mental disorders, cognitive impair-ment. Moreover, adverse metabolic effects (diabetes, weight gain, dyslipidemia, and increased cardiovascular risk) are common during treatment with APDs. Among pharmacological candidates reversing APD-induced metabolic adverse effects, glucagon-like peptide-1 (GLP-1) receptor agonists (GLP-1 RAs), approved for both diabetes and recently for obesity treatment, stand out due to their favorable effects on peripheral metabolic parameters. Interestingly, GLP-1 RAs are also proposed to have pro-cognitive effects. Particularly in terms of dual therapeutic mechanisms potentially improving both central nervous system (CNS) deficits and metabolic burden, GLP-1 RAs open a new perspective and assume a clinically advantageous position.

Links

EHP-BFNU-OVNKM-3-048-2020, interní kód MU

Name: Pharmacological reversal of metabolic derrangements induced by antipsychotic treatment in animal models

Investor: Ministry of Finance of the CR, Bilateral Fund

MUNI/A/1372/2020, interní kód MU

Name: Preklinický vývoj terapeutických přístupů k redukci nežádoucích metabolických účinků atypických antipsychotik

Investor: Masaryk University

MUNI/A/1440/2021, interní kód MU

Name: Preklinický a klinický výzkum Farmakologického ústavu v oblasti farmakokinetiky, neurobiologie závislostí a personalizované farmakoterapie v onkologii (Acronym: Farm-Pre-Klin)

Investor: Masaryk University

Citovat

HORSKÁ, Kateřina, Jana RUDÁ and Silje SKREDE. GLP-1 agonists: superior for mind and body in antipsychotic-treated patients? TRENDS IN ENDOCRINOLOGY AND METABOLISM. LONDON: ELSEVIER SCIENCE LONDON, 2022, vol. 33, No 9, p. 628-638. ISSN 1043-2760. Available from: https://dx.doi.org/10.1016/j.tem.2022.06.005.

@article{1876146,
   author = {Horská, Kateřina and Rudá, Jana and Skrede, Silje},
   article_location = {LONDON},
   article_number = {9},
   doi = {http://dx.doi.org/10.1016/j.tem.2022.06.005},
   keywords = {antipsychotic; metabolic adverse effects; GLP-1 receptor agonist; pro-cognitive; schizophrenia},
   language = {eng},
   issn = {1043-2760},
   journal = {TRENDS IN ENDOCRINOLOGY AND METABOLISM},
   title = {GLP-1 agonists: superior for mind and body in antipsychotic-treated patients?},
   url = {https://www.sciencedirect.com/science/article/pii/S1043276022001229?via%3Dihub},
   volume = {33},
   year = {2022}
}

TY  - JOUR
ID  - 1876146
AU  - Horská, Kateřina - Rudá, Jana - Skrede, Silje
PY  - 2022
TI  - GLP-1 agonists: superior for mind and body in antipsychotic-treated patients?
JF  - TRENDS IN ENDOCRINOLOGY AND METABOLISM
VL  - 33
IS  - 9
SP  - 628-638
EP  - 628-638
PB  - ELSEVIER SCIENCE LONDON
SN  - 10432760
KW  - antipsychotic
KW  - metabolic adverse effects
KW  - GLP-1 receptor agonist
KW  - pro-cognitive
KW  - schizophrenia
UR  - https://www.sciencedirect.com/science/article/pii/S1043276022001229?via%3Dihub
N2  - Antipsychotics (APDs) represent a core treatment for severe mental disorders (SMEs). Providing symptomatic relief, APDs do not exert therapeutic effects on another clinically significant domain of serious mental disorders, cognitive impair-ment. Moreover, adverse metabolic effects (diabetes, weight gain, dyslipidemia, and increased cardiovascular risk) are common during treatment with APDs. Among pharmacological candidates reversing APD-induced metabolic adverse effects, glucagon-like peptide-1 (GLP-1) receptor agonists (GLP-1 RAs), approved for both diabetes and recently for obesity treatment, stand out due to their favorable effects on peripheral metabolic parameters. Interestingly, GLP-1 RAs are also proposed to have pro-cognitive effects. Particularly in terms of dual therapeutic mechanisms potentially improving both central nervous system (CNS) deficits and metabolic burden, GLP-1 RAs open a new perspective and assume a clinically advantageous position.
ER  -

HORSKÁ, Kateřina, Jana RUDÁ and Silje SKREDE. GLP-1 agonists: superior for mind and body in antipsychotic-treated patients? \textit{TRENDS IN ENDOCRINOLOGY AND METABOLISM}. LONDON: ELSEVIER SCIENCE LONDON, 2022, vol.~33, No~9, p.~628-638. ISSN~1043-2760. Available from: https://dx.doi.org/10.1016/j.tem.2022.06.005.

Detailed Information on Publication Record